Section Arrow
DNLI.NASDAQ
- Denali Therapeutics
Quotes are at least 15-min delayed:2025/01/11 17:12 EST
Last
 19.1
-2.15 (-10.12%)
Day High 
20.8 
Prev. Close
21.25 
1-M High
25.48 
Volume 
1.30M 
Bid
19.13
Ask
20.8
Day Low
18.67 
Open
20.46 
1-M Low
18.69 
Market Cap 
3.06B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 20.78 
20-SMA 21.71 
50-SMA 24.54 
52-W High 33.33 
52-W Low 14.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.76/-1.35
Enterprise Value
3.10B
Balance Sheet
Book Value Per Share
9.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
330.53M
Operating Revenue Per Share
2.37
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/11 17:12 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brainpenetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.